Why is potassium given to a patient with DKA and hyperkalemia?

Why is potassium given to a patient with DKA and hyperkalemia?

• A. To prevent arrhythmias
• B. Depleted intracellular K+ due to transcellular shift from insulin deficiency
• C. To replace lost electrolytes
• D. To promote renal function

Answer: (B)

In the context of diabetic ketoacidosis (DKA) and hyperkalemia, potassium is administered primarily to address the intracellular depletion of potassium that occurs due to the transcellular shift resulting from insulin deficiency. In DKA, the lack of insulin leads to an inability to move potassium into cells, causing elevated serum levels of potassium (hyperkalemia). When insulin is given, it promotes the uptake of potassium into the cells, thereby correcting the hyperkalemia. This intracellular shift is crucial as while serum potassium levels may appear elevated or normal during DKA, total body potassium is often depleted due to increased renal losses and shifts. Therefore, potassium supplementation is vital to prevent further declines in serum potassium levels as treatment for DKA progresses. By focusing specifically on the transcellular dynamics of potassium during insulin therapy in DKA, this explanation affirms that the correct answer highlights the critical balance and movement of potassium in response to insulin, addressing a key physiological principle relevant to the management of this condition.

In the context of diabetic ketoacidosis (DKA) and hyperkalemia, potassium is administered primarily to address the intracellular depletion of potassium that occurs due to the transcellular shift resulting from insulin deficiency. In DKA, the lack of insulin leads to an inability to move potassium into cells, causing elevated serum levels of potassium (hyperkalemia).

When insulin is given, it promotes the uptake of potassium into the cells, thereby correcting the hyperkalemia. This intracellular shift is crucial as while serum potassium levels may appear elevated or normal during DKA, total body potassium is often depleted due to increased renal losses and shifts. Therefore, potassium supplementation is vital to prevent further declines in serum potassium levels as treatment for DKA progresses.

By focusing specifically on the transcellular dynamics of potassium during insulin therapy in DKA, this explanation affirms that the correct answer highlights the critical balance and movement of potassium in response to insulin, addressing a key physiological principle relevant to the management of this condition.